JP4651192B2 - 少なくとも一つの重合体および一つ又は複数の有効成分と複合体を形成できる少なくとも一つの化合物から成るナノ粒子およびその製造方法 - Google Patents

少なくとも一つの重合体および一つ又は複数の有効成分と複合体を形成できる少なくとも一つの化合物から成るナノ粒子およびその製造方法 Download PDF

Info

Publication number
JP4651192B2
JP4651192B2 JP2000533154A JP2000533154A JP4651192B2 JP 4651192 B2 JP4651192 B2 JP 4651192B2 JP 2000533154 A JP2000533154 A JP 2000533154A JP 2000533154 A JP2000533154 A JP 2000533154A JP 4651192 B2 JP4651192 B2 JP 4651192B2
Authority
JP
Japan
Prior art keywords
nanoparticles
active ingredient
nanoparticle
polymer
polymerization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000533154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002504526A (ja
JP2002504526A5 (https=
Inventor
ダ シルベーラ エートン モンザ
ジール ポンシェル
ドモニック ドゥシェン
パトリック クヴルール
フランシス ピュイスー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioalliance Pharma SA
Original Assignee
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma SA filed Critical Bioalliance Pharma SA
Publication of JP2002504526A publication Critical patent/JP2002504526A/ja
Publication of JP2002504526A5 publication Critical patent/JP2002504526A5/ja
Application granted granted Critical
Publication of JP4651192B2 publication Critical patent/JP4651192B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2000533154A 1998-02-27 1999-02-24 少なくとも一つの重合体および一つ又は複数の有効成分と複合体を形成できる少なくとも一つの化合物から成るナノ粒子およびその製造方法 Expired - Fee Related JP4651192B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR98/02429 1998-02-27
FR9802429A FR2775435B1 (fr) 1998-02-27 1998-02-27 Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
PCT/FR1999/000418 WO1999043359A1 (fr) 1998-02-27 1999-02-24 Nanoparticules comprenant polyisobutylcyanoacrylate et cyclodextrines

Publications (3)

Publication Number Publication Date
JP2002504526A JP2002504526A (ja) 2002-02-12
JP2002504526A5 JP2002504526A5 (https=) 2009-08-20
JP4651192B2 true JP4651192B2 (ja) 2011-03-16

Family

ID=9523473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000533154A Expired - Fee Related JP4651192B2 (ja) 1998-02-27 1999-02-24 少なくとも一つの重合体および一つ又は複数の有効成分と複合体を形成できる少なくとも一つの化合物から成るナノ粒子およびその製造方法

Country Status (12)

Country Link
US (1) US6881421B1 (https=)
EP (1) EP1056477B1 (https=)
JP (1) JP4651192B2 (https=)
AT (1) ATE311906T1 (https=)
AU (1) AU753573B2 (https=)
CA (1) CA2320928C (https=)
DE (1) DE69928776T2 (https=)
DK (1) DK1056477T3 (https=)
ES (1) ES2255246T3 (https=)
FR (1) FR2775435B1 (https=)
IL (2) IL137882A0 (https=)
WO (1) WO1999043359A1 (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582713B2 (en) 2000-04-06 2003-06-24 Univ. Of Colorado - Colorado Springs Compositions and methods for promoting wound healing
FR2808691B1 (fr) * 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
FR2816949B1 (fr) * 2000-11-17 2003-11-28 Centre Nat Rech Scient Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes
US6890703B2 (en) 2002-03-06 2005-05-10 International Business Machines Corporation Preparation of crosslinked particles from polymers having activatible crosslinking groups
EP1494649B1 (en) * 2002-04-12 2012-01-04 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
FR2841137B1 (fr) * 2002-06-20 2004-08-13 Bioalliance Pharma Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
US20050255164A1 (en) * 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
US20050051968A1 (en) * 2002-11-13 2005-03-10 Froesel David William Washer toss game
EP1761283A2 (en) * 2004-06-07 2007-03-14 California Institute Of Technology Biodegradable drug-polymer delivery system
FR2872703B1 (fr) * 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
ATE419842T1 (de) * 2004-09-14 2009-01-15 Nanodel Technologies Gmbh Abgabevehikel mit nanoteilchen
WO2006038552A1 (ja) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. 微粒子含有組成物およびその製造方法
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
KR100726720B1 (ko) 2005-12-26 2007-06-11 코스맥스 주식회사 수난용성 활성물질을 하이드록시알킬화 사이클로덱스트린과리포좀으로 이중 안정화 시킨 나노캡슐 리포좀 조성물
BRPI0713533A2 (pt) * 2006-06-26 2012-04-17 Mutual Pharmaceutical Co formulações de agente ativo, métodos de fabricação, e métodos de uso
US8679539B2 (en) * 2007-01-31 2014-03-25 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
JP5224313B2 (ja) * 2007-02-27 2013-07-03 公立大学法人横浜市立大学 プラスミド送達用粒子
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
US9132296B2 (en) 2007-05-17 2015-09-15 Ag Essence Antimicrobial solution and methods of making and using the same
US8729121B2 (en) * 2007-06-25 2014-05-20 Adhezion Biomedical, Llc Curing accelerator and method of making
EP2742875B1 (en) * 2007-11-14 2016-02-24 Adhezion Biomedical, LLC Cyanoacrylate tissue adhesives
JP5618284B2 (ja) 2007-12-27 2014-11-05 昇一 城武 グラム陽性細菌用抗菌剤
US8198344B2 (en) 2008-06-20 2012-06-12 Adhezion Biomedical, Llc Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
US8293838B2 (en) * 2008-06-20 2012-10-23 Adhezion Biomedical, Llc Stable and sterile tissue adhesive composition with a controlled high viscosity
US20110117047A1 (en) 2008-06-23 2011-05-19 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
EP2153821A1 (en) 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
US8609128B2 (en) * 2008-10-31 2013-12-17 Adhezion Biomedical, Llc Cyanoacrylate-based liquid microbial sealant drape
US9254133B2 (en) 2008-10-31 2016-02-09 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US8652510B2 (en) 2008-10-31 2014-02-18 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
PL2434886T3 (pl) 2009-05-29 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje do wstrzykiwania melfalanu zawierające pochodną cyklodekstryny i sposoby ich wytwarzania i stosowania
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
US9309019B2 (en) 2010-05-21 2016-04-12 Adhezion Biomedical, Llc Low dose gamma sterilization of liquid adhesives
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
AU2012233439A1 (en) 2011-03-31 2013-11-14 Nanocame Co., Ltd. Novel preparation technique for higher-order structure that exhibits anti-cellular effect
PL2508207T3 (pl) * 2011-03-31 2013-09-30 Bioalliance Pharma Nanocząsteczki zawierające chemioterapeutyczny lek przeciwnowotworowy
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
JP2015501197A (ja) 2011-09-23 2015-01-15 エメラルド・ヒルトン・デイビス，エルエルシー 自己組織化ナノ構造粒子およびその調製方法
US10988618B2 (en) 2011-09-23 2021-04-27 Dystar Hilton Davis Corp. Self-assembled nano-structured particle and methods for preparing
EP2805617A4 (en) * 2012-01-19 2015-08-12 Shoichi Shirotake ANTIBACTERIAL AGENT AGAINST BACTERIA CAUSING PLANT DISEASE
CN102579402B (zh) * 2012-03-26 2013-07-03 山东大学 一种负载紫杉醇的囊泡的制备方法
US11547116B2 (en) 2012-12-12 2023-01-10 William Wingfield Metal oxide compounds and infusion into polymer compounds
BR122020023215B1 (pt) 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
US10351644B2 (en) 2014-02-27 2019-07-16 Shoichi Shirotake Antiviral drug
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
WO2017046037A1 (en) 2015-09-14 2017-03-23 Onxeo Nanoparticles loaded with active ingredients, their process of preparation and their uses
WO2017144548A1 (en) 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and doxorubicin-loaded poly(cyanoacrylate) nanoparticles
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
DK4257600T3 (da) 2018-07-03 2025-05-26 Gilead Sciences Inc Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem
JP7490925B2 (ja) 2018-07-26 2024-05-28 エータイアー ファーマ， インコーポレイテッド Ｎｒｐ２関連疾患を治療するための組成物および方法
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
DK4037708T3 (da) 2019-09-30 2024-09-30 Gilead Sciences Inc HBV-vacciner og fremgangsmåder til at behandle HBV
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504408B1 (fr) * 1981-04-24 1986-02-14 Couvreur Patrick Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant
US5246611A (en) * 1990-05-09 1993-09-21 The Procter & Gamble Company Non-destructive carriers for cyclodextrin complexes
EP0548157B1 (en) * 1990-09-14 1998-05-20 Syngenix Limited Use of particulate agents
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
DE69432867T2 (de) * 1993-11-18 2004-04-22 Sirtex Medical Ltd., Burswood Zubereitung mit gesteuerter freisetzung
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin

Also Published As

Publication number Publication date
AU2628799A (en) 1999-09-15
US6881421B1 (en) 2005-04-19
FR2775435A1 (fr) 1999-09-03
JP2002504526A (ja) 2002-02-12
FR2775435B1 (fr) 2000-05-26
WO1999043359A1 (fr) 1999-09-02
EP1056477A1 (fr) 2000-12-06
CA2320928C (fr) 2009-12-15
IL137882A (en) 2006-12-31
DE69928776T2 (de) 2006-09-07
DE69928776D1 (de) 2006-01-12
IL137882A0 (en) 2001-10-31
DK1056477T3 (da) 2006-04-18
AU753573B2 (en) 2002-10-24
ATE311906T1 (de) 2005-12-15
ES2255246T3 (es) 2006-06-16
CA2320928A1 (fr) 1999-09-02
EP1056477B1 (fr) 2005-12-07

Similar Documents

Publication Publication Date Title
JP4651192B2 (ja) 少なくとも一つの重合体および一つ又は複数の有効成分と複合体を形成できる少なくとも一つの化合物から成るナノ粒子およびその製造方法
JP2002504526A5 (https=)
Govender et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug
Jain et al. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery
JP5191884B2 (ja) キトサンおよびシクロデキストリンを含んでなるナノ粒子
Nehilla et al. Purified and surfactant-free coenzyme Q10-loaded biodegradable nanoparticles
Zafar et al. Cyclodextrin containing biodegradable particles: from preparation to drug delivery applications
Cavalli et al. Enhanced antiviral activity of Acyclovir loaded into β-cyclodextrin-poly (4-acryloylmorpholine) conjugate nanoparticles
Kuo Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles
US7682635B2 (en) Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds
Rietscher et al. Impact of PEG and PEG-b-PAGE modified PLGA on nanoparticle formation, protein loading and release
Jătariu et al. Double crosslinked interpenetrated network in nanoparticle form for drug targeting—Preparation, characterization and biodistribution studies
Gao et al. Conjugates of poly (DL‐lactide‐co‐glycolide) on amino cyclodextrins and their nanoparticles as protein delivery system
Balakrishanan et al. Size-controlled synthesis of biodegradable nanocarriers for targeted and controlled cancer drug delivery using salting out cation
Jain et al. Amphotericin B loaded chitosan nanoparticles: implication of bile salt stabilization on gastrointestinal stability, permeability and oral bioavailability
WO2003027169A1 (fr) Materiau compose d'au moins un polymere biodegradable et de cyclodextrines
Arias et al. Engineering of an antitumor (core/shell) magnetic nanoformulation based on the chemotherapy agent ftorafur
García-González et al. Effect of β-cyclodextrin on the internalization of nanoparticles into intestine epithelial cells
Mainardes et al. Development of praziquantel-loaded PLGA nanoparticles and evaluation of intestinal permeation by the everted gut sac model
Kassab et al. Molecular recognition by Kluyveromyces of amphotericin B-loaded, galactose-tagged, poly (lactic acid) microspheres
Cavalli et al. Nanoparticles derived from amphiphilic γ-cyclodextrins
Babaei et al. Fabrication and evaluation of gelatin nanoparticles for delivering of anti-cancer drug
Pandey et al. Cyclodextrin based nanoparticles for improved solubility and drug delivery
Agrahari et al. Development, optimization and characterization of nanoparticle drug delivery system of Cisplatin
Ganea et al. Experimental design and multivariate analysis for optimizing poly (d, l-lactide-co-glycolide)(PLGA) nanoparticle synthesis using molecular micelles

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090522

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090622

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090629

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101119

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101214

R150 Certificate of patent or registration of utility model

Ref document number: 4651192

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees